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Objective: Patients with inherited long QT syndrome (LQTS) are prone to torsade de pointes and sudden death
(SD). Identifying affected individuals is important for SD prevention. This study aimed to determine the cause
and genotype–phenotype characteristics of LQTS in a large Omani family.
Methods:Upon LQTS diagnosis of a 5-year-old girl (proband), targetedmutation screening was performed based
on the gene-speciﬁc ECG pattern identiﬁed in her mother. ECG-guided family genotyping was conducted for
identifying additional affected individuals.
Results: ECGs of the proband demonstrated 2:1 AV block, incomplete right bundle branch block (IRBBB) and
markedly prolonged QTc (571–638ms) with bizarre T waves. Cardiac imaging revealed dilatation of the ascend-
ing aorta and pulmonary artery, and left ventricular non-compaction. Her parents were ﬁrst cousins. Both
showedmild QT prolongation, with themother presenting a LQT2 Twave pattern and the father IRBBB. Targeted
KCNH2 screening identiﬁed a novel homozygous frameshift mutation p.T1019Pfs × 38 in the proband within 3
days. Family genotyping uncovered 3 concealed LQT2 and conﬁrmed 11 members showing LQT2 ECG patterns
as heterozygous mutation carriers. All heterozygous carriers were asymptomatic, with 71% showing normal to
borderline prolonged QTc (458 ± 33 ms, range 409–522 ms).
Conclusion: p.T1019Pfs × 38, a novel KCNH2 mutation, has been identiﬁed in a large LQTS family in Oman.
Consanguineous marriages resulted in a homozygous with severe LQTS. ECG-guided phenotyping and
genotyping achieved a high efﬁciency. Genetic testing is essential in identifying concealed LQTS. Further investi-
gation is warranted to determine if there is a causative relationship between homozygous p.T1019Pfs × 38 and
cardiovascular anomaly.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).y.
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LongQT syndrome (LQTS), a cardiac ion channelopathy, is character-
ized by a prolonged QT interval on body surface electrocardiogram
(ECG) associated with increased susceptibility to torsade de pointes
(TdP) and sudden death (SD) under certain circumstances [1–4]. TdP
is an atypical type of polymorphic ventricular tachycardia (VT) mostly
seen in the presence of a markedly prolonged QT interval [3,5,6]. LQTS
can be classiﬁed as acquired and inherited though genetic predisposi-
tion also plays a role in some of the acquired forms [7]. In general,
acquired LQTS can be resolved by removing the causes, whereas
inherited LQTS is permanent due to mutations of genes encoding or
regulating cardiac potassium, sodium and calcium ion channels
[8–10]. To date, over 1000 mutations in more than 15 genes haveunder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Gene-speciﬁc ECG patterns, reﬂecting the altered electrophysiological
properties of cardiac repolarization due to mutant ion channel genes
[14], are present in the majority of LQT1-3 mutation carriers [15],
Other than the delayed ventricular repolarization and rhythm distur-
bance during cardiac events, LQTS itself does not affect cardiacmechan-
ical function at the non-event state. In other words, LQTS hearts are
otherwise healthy, which may be the reason TdP can revert to sinus
rhythm spontaneously in most cases. Nevertheless, even in a healthy
heart there is a 5% probability that TdP will degenerate into ventricular
ﬁbrillation, leading to SD [16]. Thus identifying affected individuals is
essential for SD prevention.
Currently genetic testing of known LQTS-causing genes is commer-
cially available. Once a LQTS-causingmutation is identiﬁed in one family
member, screening blood relatives can reveal additional affected mem-
bers. Family screening is a major resource for ﬁnding affected individ-
uals with LQTS [2,17] that will not only allow affected members to
take actions necessary for SD prevention but also provide relief to
non-mutation carriers. Despite these beneﬁts, commercial genetic
screening is largely not an option for families in developing countries
due to the high cost of screening for N15 known genes. However,
LQTS is a single gene disorder in most cases and the ECG phenotype is
very characteristic in LQT1-3, the most common genotypes. Performing
targeted mutational screening based on gene-speciﬁc ECG patterns
identiﬁed in one or more family member(s) can be utilized for family
genotyping. The aim of this study is to demonstrate the effectiveness
of ECG-guided phenotyping and genotyping in identifying homozygous
andheterozygous carriers of a novelKCNH2mutation in a large family in
the Sultanate of Oman.2. Methods
2.1. Study subjects
The proband, a 5-year-old girl, and her family members were en-
rolled in the study after informed written consent was obtained from
study subjects or their legal guardians.Clinical 
of t
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Fig. 1. This ﬂow chart demonstrates the strategy of ECG-guided family phenotypi2.2. ECG-guided phenotyping
ECGs of the proband and her parents were evaluated to determine if
gene-speciﬁc ECG patterns were present. Subsequently, an ECG pattern
guided family phenotyping [17] was conducted based on the screening
strategy demonstrated in Fig. 1.
A standard 12-lead ECG (0.05 Hz–100 Hz, 25 mm/s for the paper
speed and10 mm/mV for the voltage)was recorded in the supine resting
state in all subjects. At the time the ECGwas obtained, none of the partic-
ipants were taking beta-blockers or QT-prolonging drugs. ECGs were
analyzed by two investigators (K.S.A.S and L.Z.) for heart rate, rhythm,
QT interval and the presence/absence of gene-speciﬁc ECG patterns.
TheQT intervalwasmeasuredmanually in the lead showing the lon-
gestQT interval. The termination of the Twavewas taken to be thepoint
of maximal change in the slope as the T wavemerges with the base line
[2]. QT and R–R cycle length were averaged from 3 to 5 consecutive
beats. In the presence of sinus arrhythmia, average R–R cycle length
was obtained from consecutive beats in 10 s or from the heart rate.
The U wave was excluded from QT measurement. Since all ECGs were
taken in the resting state, QT was corrected (QTc) by using Bazett's
formula [18].
Family phenotyping was carried out prior to genetic testing. By fol-
lowing the screening strategy shown in Fig. 1, Individuals were consid-
ered phenotypically affected if they presented with both LQT2 T wave
patterns anddiagnostic QTc (≥470ms inmales or≥480ms in females),
and possibly affected if a LQT2 T wave pattern was present in the
absence of a diagnostic QTc [2,17].
History included LQTS-related syncope, cardiac arrest, sudden death,
and consanguineous marriage if present. A family pedigree was ﬁrst
established for the proband and her parents. It was then expanded by
following the gene-speciﬁc ECG pattern identiﬁed in blood relatives in
each generation.
Since the proband was found to have structural heart abnormalities
at birth, she had a regular follow-up every 4–6 months. Her antenatal,
pastmedical history andmedical records including ECG, 24-hourHolter,
2D-echocardiography and cardiac computed tomography (CT) were
reviewed. Echocardiogramwas also obtained fromher parents to deter-
mine whether they had structural cardiovascular abnormalities.LQTS diagnosis 
he proband
ry first-degree family member
al affected individual(s)* 
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Fig. 2. ECG characteristics in theproband andher parents. a. The toppanel shows a 12-lead
ECG of the proband. A rate-dependent IRBBB is noted. T waves are inverted in leads II, III,
aVF and V1-4. ECG tracing (Lead II) in the bottom panel demonstrates functional 2:1 AV
block. Marked QT prolongation is shown in both ECG tracings. b. A typical LQT2 T wave
morphology is shown in the mother c. The father's ECG shows IRBBB and a borderline
QT interval. His T wave morphology is atypical for LQT2.
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Informed consent, approved by and in accordance with the
guidelines of the Institutional Review Board of Baylor College of Medi-
cine, was obtained from every study subjects prior to genetic testing.
Based on the gene-speciﬁc T wave pattern shown in the mother of the
proband, we took the approach of targeted gene mutation screening.
DNA isolation, PCR and sequence analysis were performed according
to the standard protocol [11]. Brieﬂy, genomic DNA was extracted from
peripheral blood leukocytes using QIAamp DNA blood midikit
(QIAGEN). Primer pairs were designed to amplify all of the coding re-
gions and the intron–exon boundaries of KCNH2 based on the published
sequence (GenBank accession number NM_000238.3). PCR ampliﬁca-
tions were performed using standard protocols, and PCR products
were analyzed by direct sequencing on an Applied Biosystems 3730XL
Genetic Analyzer with BigDye Terminator chemistry (version 3.1). The
procedure was repeated upon identiﬁcation of mutation(s) in order to
rule out sequencing artifacts.
2.4. Statistical analysis
NCSS 2007 (Kaysville, Utah), a software for biomedical statistics,was
used for data analysis. Continuous data were expressed as mean ± SD
while categorical data were presented as counts (%). Heart rate, QRS
duration, QTc and presence of gene-speciﬁc T wave patterns were
compared between affected individuals and non-affected family
members using two-sample t tests for normally distributed variables.
Chi-square test was used for comparisons of categorical variables. A
p value of b0.05 was considered statistically signiﬁcant.
3. Results
3.1. Phenotyping
3.1.1. Proband
The proband is a 5-year-old Omani girl with a history of fetal tachy-
arrhythmia and non-immune hydrops fetalis (scalp edema and ascites)
forwhich themotherwas started on digoxin. Shewas born at termwith
a birth weight of 2.4 kg. Soon after birth she was found to have brady-
cardia with a heart rate in the range of low 60's/bpm, intermittent 2:1
AV block and paroxysmal VT. She was treated with amiodarone
and propranolol. Her initial echocardiogram after birth showed mild
left ventricular hypertrophy and a dilated ascending aorta (AscAo,
16 mm). Her cardiac systolic function was normal. Multiple 24-hour
Holter recordings showed VT runs lasting from a few seconds to a min-
ute. After onemonth of age, no VTswere noted on her Holter recordings
but she continued to have bradycardia. Amiodarone was weaned off at
the age of 6 months and the family then elected to stop propranolol at
the age of 1.5 year. At age 3.5 years, she developed her ﬁrst syncopal
episode one day after fever, vomiting, diarrhea, and acetaminophen
intake. At the local Accidental & Emergency Service, recurrent TdP was
revealed. She was treated and became hemodynamically stable. Serial
ECGs from age 3.5 to 5 years showed sinus bradycardia, increased QRS
amplitude in both right and left precordial leads, intermittent 2:1 AV
block, incomplete right bundle branch block (IRBBB), and a markedly
prolonged QT interval (QTc 612 ± 26 ms, range 571–638 ms) with
bizarre and inverted T waves in most of the 12 leads. (Fig. 2a)
A recent echocardiogram at the age of 5 years showed the following
changes: AscAo 24 mmwith a Z score of 4.5 (Fig. 3-a). Echocardiogram
also revealed that her left ventricular apex had increased trabeculations
and deep recesses that met the diagnostic criteria for left ventricular
non-compaction (LVNC, Fig. 3-b). In addition, she had a normal aortic
root size of 18.6 mm (Z score 0.21), sinotubular junction 17.8 mm
(Z score 1.4), and aortic annulus 13.2 mm (Z score 0.23) with no aortic
regurgitation. This child also had a dilated main pulmonary artery
(MPA) and branchpulmonary arterieswhichwere conﬁrmed by cardiacCT (Fig. 3-c). She had a normal pulmonary artery pressure with normal
right ventricular size and normal biventricular systolic function (EF
68%). Otherwise, she has been developing normally and event-free
with no clinical evidence ofMarfan syndromeor Loeys–Dietz syndrome.
She has normal hearing. She is continuing on propranolol with the
dose adjusted for her weight. No VTs have been detected on repeat
Holters after having re-started propranolol.
3.1.2. Parents and the extended family members
Parents of the proband are ﬁrst cousins. Both have been asymptom-
atic. Family history revealed that the proband's maternal grandmother
was having uncontrolled seizures. Despite medical therapy she died
suddenly in her 30s. Unfortunately nomedical records could be obtain-
ed. ECGs of themother showed prolonged QTc (471–499ms) with sub-
tle biﬁd T waves in most of 12-leads, an ECG pattern typically seen in
LQT2 [15,17,19]. The proband's father had an IRBBB, borderline QTc
(456–463ms)with an atypical Twavemorphology. Unlike their daugh-
ter, they had no structural cardiovascular abnormalities. The maternal
and paternal grandfathers were brothers. Both presented with a typical
LQT2 phenotype manifest, a prolonged QT interval with LQT2 T wave
bc
a
Fig. 3. Echocardiogram and cardiac CT images of the proband. a. High parasternal echocardiographic long axis view showing the diameters of the proximal aorta with clearly dilated
ascending aorta. LA: left atrium, LV: left ventricle. b. Echocardiographic short axis view of the left ventricular apex showing the prominent trabeculations and deep recesses of the non-
compacted endocardial layer (arrow). c. Computed tomography scan of the chest (axial view) showing the dilated ascending aorta (Ao), main pulmonary artery (MPA), left and right
pulmonary arteries (LPA and RPA).
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type. ECG screening each of their offspring revealed seven childrenwith
LQT2 phenotype. Overall, among 1st, 2nd and 3rd degree blood relatives
showing typical LQT2 Twave patterns, 3/11 presentedwith normal QTc
(407–440 ms), 5/11 with borderline QTc (455–465 ms) and the
remaining with moderate to markedly prolonged QTc (470–522 ms).Fig. 4. The novel frameshift mutation. Sequencing analysis of KCNH2 gene in the index patien
(c.3504delC) which causes a frameshift mutation (p.T1019Pfs × 38). Panel A represents the n
amino acids at the top. Panel B demonstrates the homozygous deletion and the corresponding
corresponding change of amino acids in her family members. The black arrow indicates the de3.2. Genetic testing and genotype–phenotype correlation
c.3504delC (p.T1019Pfs × 38), a novel homozygous frameshift mu-
tation (Fig. 4),was identiﬁed in the probandwithin 3 days after targeted
KCNH2 gene screening based on the LQT2 ECG phenotype shown in her
mother.t (proband) and her family members shows a single nucleotide deletion at position 3504
ormal control sequence of KCNH2 (GenBank accession number NM_000238.3) with the
change of amino acids in the proband. Panel C shows the heterozygous deletion and the
leted nucleotide in Panels B and C.
Fig. 5. Family pedigree. Pedigree structure demonstrates the penetrance of LQT2 through generations; and a homozygousmutation carrier (the proband) resulting from a consanguineous
marriage. The pedigree is modiﬁed to protect patient and family privacy.
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tions identiﬁed a total of 15 mutation carriers, including one homozy-
gous (proband) and 14 heterozygous carriers (Fig. 5). Table 1 shows
the phenotype characteristics of all mutation carriers with comparisons
to non-affected family members. This mutation has never before been
reported.
4. Discussion
In this study, we identiﬁed c.3504delC (p.T1019Pfs × 38a), a novel
frameshift mutation in KCNH2 gene, in 15/35 (42%) of family members
in a 4-generation Omani family. The proband is a homozygousmutation
carrier presenting with a severe LQTS phenotype, whereas 11/14
heterozygousmutation carriers presentedwith a typical LQT2 ECG phe-
notype, suggesting c.3504delC (p.T1019Pfs× 38a) closely co-segregated
with LQTS.
In the C-terminal region, c.3504delC is located in exon 13 of KCNH2,
causing p.T1019Pfs × 38a a frameshift reading error at the protein
level. Based on the functional expression results revealed in Q1070X, a
nonsense mutation 51 base-pair away, c.3504delC (p.T1019Pfs × 38)
is predicted to be a functional mutation especially when the co-
segregated genotype–phenotype is considered [19,20].
In general, nonsense and frameshift mutations can cause premature
stop codons (PTCs) in the transcribed mRNA, resulting in truncated,
incomplete, and usually nonfunctional protein products. Over 30% of
LQT2-causing mutations are nonsense and frameshift mutations thatTable 1
Phenotype characteristics in p.T1019Pfs × 38 mutation carriers and non-carriers.
Homozygous mutation carriera
Age, yrs; mean ± SD (range) 5
Male/female, (%) 0/1
Heart rate, bpm; 79 ± 12
QRS duration, ms; 99 ± 16
Functional 2:1 AV block Yes
QTc, ms; mean ± SD (range) 612 ± 26 (571–638)
T wave pattern typical to LQT2, No (%) No
LQTS-related symptoms Syncope
a ECG values of the proband were obtained from serial ECGs.
b p b 0.001 when compared with non-mutation carriers in the family.can introduce PTCs. Nevertheless, an evolutionary surveillance called
nonsense-mediatedmRNAdecay (NMD) pathway can detect and selec-
tively degrade defective mRNA transcripts containing PTCs, thereby
preventing the synthesis of truncated and potentially harmful proteins
[19–21]. As such, dominant-negative effects from truncated proteins
can be converted to haploin sufﬁciency. In fact, heterozygous Q1070X
carriers of anArabian family reported byBihuiyan, et al. [20] andhetero-
zygous p.T1019Pfs × 38a carriers of an Omani family in our study, all
presented with mild LQT2 phenotypes. It is interesting to note that the
IRBBB is shown in both the father and daughter, indicating that such
an ECG pattern can be inherited as well since the prevalence of IRBBB
is only 2% in the general population.
Oman is an Arab state on the southeastern coast of the Arabian
Peninsula. Consanguineous marriage is a marriage between blood rela-
tives. Consanguineous marriage is practiced in most Arab and Middle
Eastern countries, including Oman. More than half (52%) of marriages
are consanguineous. First cousin marriages are the most common, con-
stituting 39% of all marriages and 75% of all consanguineous marriages
in Oman [22]. The parents of the proband are ﬁrst cousins and both
are heterozygous carriers of T1019Pfs × 38a mutation. The chance that
each of their offspring becomes a heterozygous, a homozygous or a
non-mutation carrier is 50%, 25% and 25%, respectively (Fig. 6). Such a
pattern of autosomal dominant inheritance, in the setting of both
parents being heterozygous, is actually the same as autosomal recessive
inheritance. Due to the nature of consanguinity, it is anticipated that
additional genetic defects, especially autosomal recessive disorders,Heterozygous mutation carriers Non-mutation carriers
26 ± 21 (4–82) 23 ± 13 (0.9–54)
10/4 10/10
78 ± 15 76 ± 15
85 ± 12 84 ± 11
No No
458 ± 33 (407–522)b 409 ± 28 (355–459)
11/14 (79%)b 0/20 (0)
No No
Fig. 6. Pattern of inheritance.
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seven siblings. Two of them suffer from congenital deafness even
though they do not carry this KCNH2 mutation. Congenital deafness is
fairly common in Omani families with consanguineous marriages [23].
The proband carries two doses of T1019Pfs × 38a mutation. As
predicted, the NMD effects [19–21] may have led to a nearly complete
elimination of hERG channels, therefore producing a severe LQTS
phenotype [19,20,24]. The severe clinical phenotype observed in the
proband is consistent with a simulation study in a cardiac ventricular
cell model [25]. The computer simulation study shows that a 75–100%
reduction of hERG channel currents can prolong action potential
duration sufﬁciently to generate early after depolarizations, which
may trigger life-threatening arrhythmias. Indeed the proband had an
early onset of cardiac events due to recurrent TdP. Her ECG displayed
an extremely prolonged QT interval, which at times, caused functional
2:1 AV block because every other P wave of sinus node origin appeared
on the ascending portion of the T wave of the previous beat (Fig. 2a)
when the AV conduction system was absolutely refractory. In LQTS,
functional 2:1 AV block is reported in children with LQT3 [26,27],
LQT8 (Timothy syndrome) [28] or compound mutations of LQTS [29]
with a severe phenotype.
The ECG of the proband displayed a bizarre and inverted T wave in
most of the 12 leads, which is atypical for LQT2. Indeed most of LQT2
patients present with gene-speciﬁc T wave patterns except those carry-
ing compound mutations. To our knowledge, the proband is the ﬁrst
case of LQTS associated with dilatation of the ascending aorta and
pulmonary arteries, and the development of LVNC. Those changes are
different fromMarfan syndrome, Loeys–Dietz syndrome, or other read-
ily explainable syndromes. Neither parents of the proband nor other
family members had such changes. To date, LVNC has been reported
in several patients showing severe LQTS phenotype and they happen
to be the mutation carriers of KCNQ1 [30], KCNH2 [31] and SCN5A [32].
The proband in our study is the 3rd case of LVNC carrying a KCNH2
mutation. Whether it is caused by homozygous p.T1019Pfs × 38
or other genetic defects will require further investigations, which is
beyond the scope of current study.
Based on our experience, most LQTS cases are identiﬁed via family
screening [17,19,33]. Since LQT2 is one of the most common subtypes
of LQTS with gene-speciﬁc ECG pattern shown in the majority of gene
carriers, once a LQT2 ECG pattern is identiﬁed in a LQTS subject,
performing ECG-guided family screening has been proven to be a highlyeffective approach not only in improving the diagnostic accuracy but
also in ﬁnding the gene mutation. In this study we bypassed 15 LQTS
gene screening tests [13] that otherwise could cost a fortune to the
family. A targeted KCNH2 gene screening only took 3 days to identify
the mutation with minimal cost. ECG-guided family phenotyping re-
vealed family branches to which the disease had penetrated. Genotyp-
ing everyone in a branch where one or more members express a LQT2
phenotype can also identify concealed cases. A total of 15 LQTS patients,
80% children and young adults, have been identiﬁed via ECG-guided
phenotyping and genotyping. This cost-effective approach is especially
suitable to patients and families in developing countries since the
gene-speciﬁc ECG patterns can easily be recognized. Knowledge of
genotype will help the affected individuals avoid QT prolonging drugs
and metabolic factors that could predispose to TdP.
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